0001127602-20-030007.txt : 20201125
0001127602-20-030007.hdr.sgml : 20201125
20201125162112
ACCESSION NUMBER: 0001127602-20-030007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201123
FILED AS OF DATE: 20201125
DATE AS OF CHANGE: 20201125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoge Stephen
CENTRAL INDEX KEY: 0001760669
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 201350865
MAIL ADDRESS:
STREET 1: C/O MODERNA, INC.
STREET 2: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-11-23
0001682852
Moderna, Inc.
MRNA
0001760669
Hoge Stephen
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
President
Common Stock
2020-11-23
4
M
0
10000
.99
A
1754597
D
Common Stock
2020-11-23
4
S
0
1400
99.34
D
1753197
D
Common Stock
2020-11-23
4
S
0
6912
100.12
D
1746285
D
Common Stock
2020-11-23
4
S
0
6688
101.22
D
1739597
D
Common Stock
2020-11-24
4
S
0
100
94.23
D
1739497
D
Common Stock
2020-11-24
4
S
0
500
95.65
D
1738997
D
Common Stock
2020-11-24
4
S
0
908
97.27
D
1738089
D
Common Stock
2020-11-24
4
S
0
2592
98.35
D
1735497
D
Common Stock
2020-11-24
4
S
0
900
99.06
D
1734597
D
Common Stock
4116
I
By Valhalla, LLC
Common Stock
151933
I
By Trust
Stock Option (Right to Buy)
.99
2020-11-23
4
M
0
10000
0
D
2023-08-19
Common Stock
10000
717431
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.70 to $99.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.72 to $100.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.82 to $101.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.29 to $95.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.80 to $97.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.81 to $98.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.83 to $99.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
This option is fully vested and exercisable.
/s/ Lori Henderson, as Attorney-in-Fact
2020-11-25